

Oncoinvent lists on Euronext Growth Oslo

- **Market capitalisation of approximately NOK 184 million**
- **The 45th listing on Euronext in 2024 and the 11th listing on Euronext Oslo Børs' markets**
- **New Euronext IPO ready alumnus to successfully complete a listing**



Oslo- 13 December 2024 – Euronext today congratulates the pharmaceutical company Oncoinvent (ticker:ONCIN) on its listing on Euronext Growth Oslo. This marks the 11th listing on Euronext Oslo Børs' markets in 2024 and the 45th listing on Euronext.

Oncoinvent specialises in developing innovative cancer treatments. Its flagship therapy involves the injection of radioactive microparticles into the abdominal cavity to target residual cancer cells following surgery. This groundbreaking treatment is specifically designed for patients with colon or ovarian cancer, aiming to offer improved therapeutic options for those affected.

The company raised NOK 130 million through a private placement ahead of its listing. The price was NOK 2 per share before market opening, giving the company a market capitalisation of approximately NOK 184 million.

Oncoinvent was a participant in IPOready 2024, Euronext's unique pan-European business educational pre-IPO programme aiming to support European companies considering a listing. Euronext's pre-IPO programmes have a proven track record, having already trained over 920+ alumni since 2015. In total 31 alumni have listed their company on Euronext markets, and Oncoinvent is the first Norwegian alumnus.

Øystein Soug, CEO of Oncoinvent, said: "Oncoinvent is thrilled to join Euronext Growth Oslo, a milestone that underscores our commitment to advancing innovative cancer therapies. This listing will enhance our visibility, attract new investors, and provide the financial flexibility and stability needed to accelerate our clinical development program to data in 2025 and 2026. We look forward to leveraging this platform to drive growth, not only of Oncoinvent but eventually also of the Oslo radiopharma ecosystem."



Caption: Øystein Soug, CEO of Oncoinvent, and his team rang the bell today to celebrate the company's listing on Euronext Growth Oslo. The company was welcomed by Øivind Amundsen, CEO of Euronext Oslo Børs and Eirik Høiby Ausland, Head of Listings Nordics in Euronext. (Photo: Thomas Brun | NTB).

CONTACTS

MEDIA – mediateam@euronext.com

Norway

Cathrine Lorvik Segerlund

+47 41 69 59 10

About Oncoinvent

Oncoinvent is a clinical-stage company committed to developing innovative radiopharmaceuticals against cancer. The lead candidate Radspherin is designed for targeted local treatment of metastatic cancers in body cavities using highly potent alpha radiation. It is currently evaluated in a Phase 2 randomised controlled study of ovarian cancer, building on previous encouraging safety data and signals of efficacy. The Oncoinvent team has experience from all stages of radiopharmaceutical development.

About Euronext

Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.3 trillion in market capitalisation as of end of September 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe's leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs. For the latest news, go to euronext.com or follow us on X (x.com/euronext) and LinkedIn (linkedin.com/company/euronext)

Disclaimer

This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided "as is", without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at www.euronext.com/terms-use.

© 2024, Euronext N.V. - All rights reserved.

The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, "GDPR"), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: www.euronext.com/privacy-policy. In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights, please refer to: www.euronext.com/data_subjects_rights_request_information. To make a request regarding the processing of your data or to unsubscribe from this press release service, please use our data subject request form at connect2.euronext.com/form/data-subjects-rights-request or email our Data Protection Officer at dpo@euronext.com.